Neoleukin Therapeutics, Inc. (NLTX)
Market Cap | 32.89M |
Revenue (ttm) | n/a |
Net Income (ttm) | -57.56M |
Shares Out | 47.30M |
EPS (ttm) | -1.04 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 209,816 |
Open | 0.690 |
Previous Close | 0.695 |
Day's Range | 0.675 - 0.700 |
52-Week Range | 0.375 - 2.320 |
Beta | 1.19 |
Analysts | Sell |
Price Target | 2.04 (+193.4%) |
Earnings Date | May 8, 2023 |
About NLTX
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neole... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for NLTX stock is "Sell." The 12-month stock price forecast is $2.04, which is an increase of 193.40% from the latest price.
News

Neoleukin (NLTX) Up 36% on Initiating Another Restructuring Plan
Neoleukin (NLTX) seeks strategic options to maximize shareholder's value. This includes the undertaking of another restructuring plan to reduce 70% of the existing workforce.

Shares of Neoleukin Therapeutics spike after announcing layoffs and potential sale or merger
Neoleukin Therapeutics is slashing its workforce by about 70% as it seeks “strategic alternatives” for its future, according to a company statement Wednesday.

Neoleukin Therapeutics Provides Strategic Update and Announces Restructuring and Leadership Transition
SEATTLE, March 08, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein...

Neoleukin Therapeutics Presents Preclinical Data on NEO-TRA1 at American Society of Hematology (ASH) Annual Meeting
Targeted, precision-tuned agonist of IL-2 receptor selectively expands regulatory T cells Targeted, precision-tuned agonist of IL-2 receptor selectively expands regulatory T cells

Neoleukin (NLTX) Stops Development of Lead Drug, Stock Down
Due to discontinuing the development of its lead candidate, Neoleukin (NLTX) has no pipeline candidates in clinical development. Management undertakes restructuring initiatives to curb cash burn.

Neoleukin Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Update
-- Development of NL-201 to be discontinued for strategic reasons -- -- Company to focus on next-generation de novo proteins and core technology -- -- Company restructuring to extend cash runway into ...

Neoleukin Therapeutics Announces Oral Presentation at 64th American Society of Hematology (ASH) Annual Meeting
SEATTLE, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein ...

Neoleukin Therapeutics Announces Second Quarter 2022 Financial Results & Provides Corporate Update
Company to Host Conference Call Today, August 9, 2022, at 1:30 p.m. Pacific / 4:30 p.m. Eastern Company to Host Conference Call Today, August 9, 2022, at 1:30 p.m. Pacific / 4:30 p.m. Eastern

Neoleukin Therapeutics to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 9, 2022
SEATTLE, July 27, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin” (NASDAQ:NLTX), today announced it will report second quarter 2022 financial results on Tuesday, August 9, 2022 afte...

Neoleukin Therapeutics Announces First Quarter 2022 Financial Results and Corporate Update
SEATTLE, May 09, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein t...

Neoleukin Therapeutics to Present at Upcoming Investor Conferences
SEATTLE, May 05, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein t...

Neoleukin Therapeutics Announces Preclinical Data for NL-201 at American Association for Cancer Research (AACR) Annual Meeting
- NL-201 demonstrates antitumor activity in preclinical B-cell lymphoma models -

Neoleukin Therapeutics to Present at Canaccord Genuity Horizons in Oncology Conference
SEATTLE, April 07, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein...

Neoleukin Therapeutics Announces Multiple Presentations at American Association for Cancer Research (AACR) Annual Meeting
SEATTLE, March 08, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein...

Neoleukin Therapeutics Announces Year End 2021 Financial Results and Corporate Update
- Interim data from NL-201 Phase 1 trial for patients with relapsed and refractory solid tumors anticipated in the second half of 2022 –

Neoleukin Therapeutics Announces Clinical Collaboration with Merck to Evaluate NL-201 in Combination with KEYTRUDA® (pembrolizumab)
- NL-201 plus pembrolizumab to be evaluated in advanced solid tumor patients - - Combination testing anticipated to begin in 2022 -

Neoleukin Therapeutics Presenting at H.C. Wainwright BIOCONNECT Virtual Conference
SEATTLE, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein ...

Neoleukin Therapeutics Announces Preclinical Data Highlighting Activity of NL-201 in Hematologic Malignancies at 63rd American Society of Hematology Annual Meeting (ASH 2021)
– Poster presentation highlights NL-201 activity in multiple myeloma stem cell transplant model – – Abstract reports activity of NL-201 as monotherapy and anti-PD1 combination in non-Hodgkin lymphom...

Neoleukin Therapeutics Presents NL-201 Preclinical Data at Society for Immunotherapy of Cancer's 36th Annual Meeting (SITC 2021)
SEATTLE, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein ...

Neoleukin Therapeutics Announces Multiple Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer's 36th Annual Meeting (SITC 2021)
SEATTLE, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein ...

Neoleukin Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
SEATTLE, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein...

Neoleukin Therapeutics to Participate in Jefferies Virtual Healthcare Conference
SEATTLE, May 26, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein t...

Neoleukin Therapeutics Announces First Quarter 2021 Financial Results and Corporate Update
- Entered clinical development with first patient dosed in Phase 1 Trial of NL-201 -

Neoleukin's IL-2 Agonist Candidate Cleared To Start Phase 1 Trial In Solid Tumors
The FDA has removed the clinical hold related to Neoleukin Therapeutics Inc (NASDAQ: NLTX) investigational new drug application, to begin a Phase 1 program of its cancer immunotherapeutic candidate, N...

Neoleukin Therapeutics Announces Year End 2020 Financial Results
- Anticipating first patient for NL-201 Phase 1 Trial in 1H21 -